云南白药(000538) - 2015 Q3 - 季度财报

Financial Performance - Operating revenue for the current period was CNY 5.15 billion, up 9.70% year-on-year[7] - Net profit attributable to shareholders for the current period was CNY 886.84 million, an increase of 8.89% year-on-year[7] - Net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 851.77 million, up 6.16% year-on-year[7] - Basic earnings per share for the current period was CNY 0.85, an increase of 8.89% year-on-year[7] - Total operating revenue for the period reached ¥5,145,199,663.59, an increase of 9.7% compared to ¥4,690,115,853.86 in the previous period[37] - Net profit for the period was ¥882,849,247.43, compared to ¥808,494,010.67 in the previous period, representing a growth of 9.2%[38] - Total operating revenue for the period reached CNY 14.69 billion, an increase of 10.3% compared to CNY 13.32 billion in the previous period[45] - Net profit attributable to shareholders was CNY 2.14 billion, compared to CNY 1.94 billion in the previous period, marking an increase of 10.2%[46] - The company reported a total profit of CNY 2.50 billion, an increase from CNY 2.26 billion, which is a growth of 10.6%[46] - The comprehensive income attributable to shareholders was CNY 2.14 billion, compared to CNY 1.94 billion in the previous period, showing an increase of 10.2%[47] Assets and Liabilities - Total assets increased by 15.10% to CNY 18.81 billion compared to the end of the previous year[7] - The total liabilities of the company were CNY 5.90 billion, up from CNY 5.05 billion, marking an increase of approximately 16.8%[31] - The company's total current liabilities increased to CNY 4.82 billion from CNY 3.94 billion, indicating a rise of about 22.3%[31] - The total accounts payable increased by 43.95% to RMB 2,953,187,327.05, primarily due to increased payables from Yunnan Pharmaceutical Co., Ltd.[15] - The company's short-term borrowings remained stable at CNY 20 million, unchanged from the previous period[30] Cash Flow - The net cash flow from operating activities for the year-to-date was CNY 1.92 billion, an increase of 39.11%[7] - Net cash flow from operating activities increased by 39.11% to RMB 1,915,636,314.98, attributed to sales growth and bank acceptance bill collection[15] - Cash inflow from operating activities totaled CNY 16,606,302,920.86, an increase from CNY 15,058,148,009.15 year-over-year[53] - Net cash flow from operating activities was CNY 1,915,636,314.98, up from CNY 1,377,060,448.86 in the previous period[53] - Cash outflow from investing activities was CNY 1,331,828,380.39, compared to CNY 1,556,659,477.16 in the previous period[54] - Cash flow from financing activities resulted in a net outflow of -CNY 604,534,078.05, compared to -CNY 406,084,293.23 in the previous period[54] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 33,827[11] - The largest shareholder, Yunnan Baiyao Holdings Co., Ltd., held 41.52% of the shares[11] - The company did not engage in any repurchase transactions among its top shareholders during the reporting period[15] Investments and Financial Assets - The company's financial assets measured at fair value increased by 407.33% to RMB 2,213,800,484.61 compared to RMB 436,365,087.25 at the beginning of the period due to increased purchases of money market funds[15] - The company's investment income rose by 109.79% to RMB 111,613,447.63, benefiting from returns on financial products and trading financial assets[15] - The company reported an investment income of ¥38,382,249.75, up from ¥23,402,689.90, indicating a significant increase of 63.8%[38] Inventory and Receivables - Inventory levels rose to CNY 5.68 billion, compared to CNY 4.98 billion at the start of the period, indicating an increase of approximately 13.8%[29] - Accounts receivable rose by 112.02% to RMB 1,176,442,815.36, driven by revenue growth from subsidiary Yunnan Pharmaceutical Co., Ltd.[15] - Accounts receivable decreased to CNY 1.18 billion from CNY 0.55 billion, showing a significant increase of about 112.5%[29] - Prepayments increased by 71.65% to RMB 495,977,868.12, reflecting higher advance payments for goods[15] Financial Ratios and Returns - The weighted average return on equity was 7.02%, a decrease of 0.95% compared to the same period last year[7] - Basic and diluted earnings per share remained stable at CNY 2.06, compared to CNY 1.87 in the previous period[47] Other Financial Metrics - The company experienced an asset impairment loss of CNY 18.79 million, compared to a gain of CNY 14.75 million in the previous period[45] - The report was not audited, indicating that the figures are preliminary and subject to change[59]